Structure Therapeutics Inc. (NASDAQ: GPCR) is making a case that the future of weight-loss drugs might not require a needle. On Tuesday, the company unveiled fresh clinical data for two of its oral candidates, ACCG-2671 and aleniglipron, both aimed at metabolic conditions and chronic weight management. The results, while early, suggest the company is making steady progress in a crowded and competitive field.

Let's start with ACCG-2671, the newer of the two. In a Phase 1/2a single ascending dose study, 31 healthy, non-obese participants received doses ranging from 1 mg to 10 mg. The drug showed rapid absorption and a terminal half-life of roughly six days, which means it could be dosed daily or even weekly. That flexibility could be a big selling point if it holds up in later trials.

The efficacy signal was encouraging too. A single 10 mg dose led to a 3.3% mean body weight reduction by Day 24. The drug also cut CTX-1, a bone resorption biomarker, by about 60% on Day 2. That's notable because some GLP-1 drugs have raised concerns about bone density loss. No serious adverse events or liver enzyme elevations were reported, though higher doses did come with dose-related gastrointestinal side effects, which is par for the course in this class.

Buoyed by these results, Structure has already kicked off a multiple ascending dose trial, with data expected in the first half of 2027.

Meanwhile, aleniglipron, the company's more advanced candidate, continues to show staying power. In the ACCESS open-label extension study, adults who kept taking the daily oral pill saw sustained weight loss through 72 weeks. Those on the 180 mg maximum dose achieved up to 16.2% body weight loss, and notably, they hadn't hit a plateau yet. That's a strong signal for durability.

Tolerability also looked manageable. Starting patients on a lower 2.5 mg dose helped ease gastrointestinal side effects, and fewer than 5% of participants dropped out due to adverse events. In a world where many patients abandon GLP-1s because of side effects, that's a meaningful data point.

These findings come as Structure pushes forward with its Phase 3 ACCOMPLISH program for aleniglipron, which began in August 2026. Topline data from that study is expected in the second half of 2028, so there's still a long road ahead. But the company isn't waiting around. It plans to report three separate trial readouts in the fourth quarter of 2026, covering body composition, type 2 diabetes, and transitioning patients from injectable GLP-1 medicines to oral aleniglipron. That last one could be particularly interesting, as it speaks directly to the convenience factor that oral drugs might offer over injections.

Investors, however, seemed less enthusiastic on Tuesday. Structure Therapeutics shares were down 8.45% at $43.34 at the time of publication, according to market data. That might reflect profit-taking or broader market jitters, but the clinical narrative here is one of steady progress.

The weight-loss drug market is getting crowded, with big pharma and biotech players all vying for a piece of the pie. Structure's bet on oral formulations could differentiate it, but the proof will be in the larger, longer trials. For now, the data adds another brick to the foundation.